Pacira BioSciences' Cash from Operations rose 1282.27% to $60.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $141.4 million, marking a year-over-year decrease of 3061.41%. This contributed to the annual value of $189.4 million for FY2024, which is 2246.38% up from last year.
Latest data reveals that Pacira BioSciences reported Cash from Operations of $60.8 million as of Q3 2025, which was up 1282.27% from $12.0 million recorded in Q2 2025.
In the past 5 years, Pacira BioSciences' Cash from Operations registered a high of $60.8 million during Q3 2025, and its lowest value of $12.0 million during Q2 2025.
In the last 5 years, Pacira BioSciences' Cash from Operations had a median value of $42.0 million in 2022 and averaged $38.1 million.
Per our database at Business Quant, Pacira BioSciences' Cash from Operations soared by 29286.99% in 2021 and then crashed by 7743.63% in 2025.
Quarter analysis of 5 years shows Pacira BioSciences' Cash from Operations stood at $23.2 million in 2021, then soared by 81.08% to $42.0 million in 2022, then increased by 13.2% to $47.6 million in 2023, then plummeted by 30.37% to $33.1 million in 2024, then soared by 83.61% to $60.8 million in 2025.
Its last three reported values are $60.8 million in Q3 2025, $12.0 million for Q2 2025, and $35.5 million during Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value